Innovent Bio and IASO Biotechnology Announced National Medical Products Administration Approval for FUCASO
By, Admin1 min read
Share
Innovent Biologics and IASO Biotechnology announced that the China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
